Cristian Rodriguez-Aguayo

The University of Texas MD Anderson Cancer Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

2h-index23citations116works2.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related molecular mechanisms research(27), RNA modifications and cancer(22), RNA Interference and Gene Delivery(20), Cancer Mechanisms and Therapy(15), MicroRNA in disease regulation(14)

Publications116 total

Epigenetic modulation of BARD1 to enhance anti-VEGF therapy
Cell Reports Medicine·2025· 2 citedOpen Access
Abstract 2720: Enhancing oral delivery of plant-derived vesicles
Cancer Research·2023
Supplementary Figures 1-7 from Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma
2023Open Access
Data from Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
2023Open Access
Supplementary Figure Legends, Materials and Methods, and Table 1 from Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma
2023Open Access
Supplemental Figure 3 from Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
2023Open Access
Supplementary Figures 1 - 2 from Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs
2023Open Access
Data from Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs
2023Open Access
Data from Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
2023Open Access
Supplementary Tables 1-2 from Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
2023Open Access
Data from Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs
2023Open Access
Supplemental Table 1 from Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
2023Open Access
Supplementary Figures 1 - 2 from Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs
2023Open Access
Supplementary Figures 1-12 from Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
2023Open Access
Supplemental Figure 1 from Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
2023Open Access
Supplementary Figure Legends, Materials and Methods, and Table 1 from Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma
2023Open Access
Data from Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
2023Open Access
Supplemental Figure 4 from Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
2023Open Access
Supplemental Figure 4 from Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
2023Open Access
Supplementary Figures 1-12 from Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Gabriel Lopez‐Berestein(50), Anil K. Sood(39), Cristina Ivan(24), Xinna Zhang(18), George A. Călin(18), Lingegowda S. Mangala(14), Sunila Pradeep(14), Rajesha Rupaimoole(13), Vianey González-Villasana(13), Milena S. Nicoloso(11), Simona Rossi(11), Sherry Y. Wu(10), Nicholas B. Jennings(10), Chad V. Pecot(10), Enrique Fuentes‐Mattei(9), Lianchun Xiao(9), Roxana S. Redis(9), Ioana Berindan‐Neagoe(9), Massimo Negrini(9), Burcu Aslan(9)